Home/Pipeline/INCB099280

INCB099280

Advanced Solid Tumors

Phase 1/2Active

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1/2

Status

Active

Company

Incyte

About Incyte

Incyte is a publicly traded, revenue-generating biopharmaceutical company with a market valuation of approximately $18.19 billion, built on a foundation of targeted small molecule science. Its commercial success is anchored by Jakafi® (ruxolitinib) in myelofibrosis and polycythemia vera, with a diversified pipeline extending into oncology and immunology. The company's strategy combines internal R&D excellence with strategic partnerships to expand its therapeutic footprint and commercial reach globally.

View full company profile

Therapeutic Areas

Hematology Oncology Inflammation & Autoimmunity

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BI-1808	BioInvent International	Phase 1/2a	Active
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active
IT-141 (Etoposide IVECT™)	Intezyne	Phase 1	Active
NC318	NextCure	Phase 1/2	Discontinued (Monotherapy)
VisAcT (18F-AraG) Imaging in Solid Tumors	CellSight Technologies	Phase 1/2	Active